Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 21 April 2017

IBA SA - basic data - update following capital increase dated 21 April 2017

IBA SA    

Published: 11:00 CEST 21-04-2017 /GlobeNewswire /Source: IBA SA / : IBAB /ISIN: BE0003766806


Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008


Louvain-la-Neuve, Belgium, April 21, 2017, 11 a.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated April 21, 2017.


Communication of the basic data as per Article 15 §1 al.1 of the Law


  • Total capital:                                                                                           EUR 41 899 278.10
  • Total number of securities conferring the voting right:                          29 852 549 (of which 12 702 489 with VVPR strips)
  • Total number of voting rights (= the denominator):                               29 852 549
  • Total number of securities conferring the voting right, by category:     N/A
  • Total number of voting rights, by category:                                           N/A



Communication of the additional data as per Article 15 §1 al.2 of the Law


  • Total number of convertible bonds conferring the voting right:                      0
  • Total number of rights, materialized or not by certificates, giving the
    right to subscribe to newly issued securities conferring the voting right
    (e.g. warrants):                                                                                                509 850
  • Total number of voting rights which would result from the exercise of
    these conversion or subscription rights:                                                          509 850
  • Total number of shares without voting right:                                                   0



Statutory thresholds as per Article 18 of the Law


The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent




About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.


IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com



For further information, please contact:




Caroline Hardy

Corporate Legal Counsel

+32 10 201 159



20170421 evolution of the basic data EN

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: IBA SA, Chemin du Cyclotron 3, Louvain-la-Neuve 1348, Belgium
If you would like to unsubscribe and stop receiving these e-mails click here.